BI 836858 clinical trials
Also written BI 836858.
How each study uses BI 836858 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the BI 836858 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BI 836858
- 4
Studies by the year they started
5 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Boehringer Ingelheim (3) · Philogen S.p.A. (1) · Beat AML, LLC (1)
Often tested with
Tested in the same studies.
Samalizumab (1) · Cytarabine (1) · Azacitidine (1) · Enasidenib (1) · Entospletinib (1) · Pevonedistat (1) · Ivosidenib (1) · Gilteritinib (1)
Studies
Open first, then newest update. How each study uses BI 836858 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaRecruitingPhase 2/3Beat AML, LLCNCT03013998Written as BI 836858 (BAML-16-001-S2)How we know
- BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to RelapseCompletedPhase 1Boehringer IngelheimNCT01690624Written as BI 836858How we know
- A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)CompletedPhase 1/2Boehringer IngelheimNCT02632721Written as BI 836858How we know
- Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell TransplantationCompletedPhase 1Philogen S.p.A.NCT03207191Written as BI 836858How we know
- Phase I/II Trial to Investigate BI 836858 in Myelodysplastic SyndromesTerminatedPhase 2Boehringer IngelheimNCT02240706Written as BI 836858How we know